

(19)



(11)

EP 2 222 326 B1

(12)

EUROPEAN PATENT SPECIFICATION

(45) Date of publication and mention of the grant of the patent:
18.04.2012 Bulletin 2012/16

(51) Int Cl.:
A61K 38/07 (2006.01) A61K 31/506 (2006.01)

(21) Application number: **08852880.7**

(86) International application number:
PCT/EP2008/065925

(22) Date of filing: **20.11.2008**

(87) International publication number:
WO 2009/065897 (28.05.2009 Gazette 2009/22)

(54) Inhibitors of MALT1-proteolytic activity and uses thereof

Inhibitoren der MALT1-proteolytischen Aktivität und ihre Verwendung

Inhibiteurs d'activité protéolytique de MALT1 et leur utilisations

(84) Designated Contracting States:
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR

(30) Priority: **21.11.2007 EP 07121200**
21.11.2007 US 4097

(43) Date of publication of application:
01.09.2010 Bulletin 2010/35

(73) Proprietors:
• **VIB VZW**
9052 Gent (BE)
• **Universiteit Gent**
9000 Gent (BE)
• **Katholieke Universiteit Leuven, K.U. Leuven R&D**
3000 Leuven (BE)

(72) Inventors:
• **BEYAERT, Rudi**
B-9750 Zingem (BE)
• **MARYNEN, Peter**
B-3020 Herent (BE)
• **BAENS, Thijs**
B-3210 Lubbeek (BE)
• **HEYININCK, Karen**
B-9860 Scheldewindeke (BE)

(56) References cited:
US-A1- 2004 110 145 US-A1- 20030 229 108
US-A1- 20070 203 236

• **PRIVÉ ET AL: "Specific peptides for the therapeutic targeting of oncogenes" CURRENT OPINION IN GENETICS & DEVELOPMENT, vol. 16, 2006, pages 71-77, XP005250171**

- **INAGAKI: "Mucosa-associated lymphoid tissue lymphoma: Molecular pathogenesis and clinicopathological significance" PATHOLOGY INTERNATIONAL, vol. 57, August 2007 (2007-08), pages 474-484, XP002473988**
- **JOHNSON ET AL: "Anthrax lethal factor protease inhibitors: Synthesis, SAR, and structure-based 3D QSAR studies" JOURNAL OF MEDICINAL CHEMISTRY, vol. 49, 12 January 2005 (2005-01-12), pages 27-30, XP002584242**
- **COORNAERT ET AL: "T cell antigen receptor stimulation induces MALT1 paracaspase-mediated cleavage of the NF-kB inhibitor A20" NATURE IMMUNOLOGY, vol. 9, March 2008 (2008-03), pages 263-271, XP002473989**
- **MCALLISTER-LUCAS ET AL: "Finally, MALT1 is a protease !" NATURE IMMUNOLOGY, vol. 9, March 2008 (2008-03), pages 231-233, XP002474046**
- **REBEAUD ET AL: "The proteolytic activity of the paracaspase MALT1 is key in T cell activation" NATURE IMMUNOLOGY, vol. 9, March 2008 (2008-03), pages 272-281, XP002474047**
- **N.N.: "MALT1 and A20: partners in inflammation" VIBNEWS, no. 35, March 2008 (2008-03), page 1, XP002474048 Retrieved from the Internet: URL: www.vib.be/NR/rdonlyres/8967026B-F4D2-47D1-A124-5E7C00B128D1/2504/vibnewsIssue35_March2008protected.pdf [retrieved on 2008-03-26]**
- **THOME: "Molecular mechanisms of lymphocyte activation and survival" BIOCHEMISTRY UNIL / UNIVERSITÉ DE LAUSANNE, 2008, pages 1-7, XP002474142 Retrieved from the Internet: URL: www.unil.ch/ib/page9498.html [retrieved on 2008-03-27]**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 2 222 326 B1